Antiaging Quantum Living Inc (AAQL)

[maverick_1]

ARWR: Arrowhead cleared to proceed to Phase 2b for hep B candidate

The FDA gives the green light to Arrowhead Research (NASDAQ:ARWR) to initiate a Phase 2b study of ARC-520 for the treatment of chronic hepatitis B infection. The study, called Heparc-2004, will involved 12 patients, eight will receive 1 mg/kg of ARC-520 and four will receive placebo.The trial is designed to assess multiple doses of ARC-520 (2 mg/kg and 4 mg/kg) but FDA has a partial clinical hold in place until it reviews data from the 1 mg/kg arm.The company expects to begin patient enrollment in ~1 month.Previously: Arrowhead drops after FDA partial clinical hold on hep B candidate (Jan. 12)

Coupled with my 1st post on ACHN, this is why I've preferred ARWR over the last two months for a whole host of portfolio reasons just like what is evolving on NWBO.